Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II perioperative trastuzumab rezetecan + camrelizumab in HER2-positive muscle-invasive urothelial carcinoma
ChiCTR2600126897Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital, Anhui Medical University
- Start
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab rezetecan and camrelizumab in transitional cell carcinoma of the bladder (TCC), sponsored by The First Affiliated Hospital, Anhui Medical University. Primary endpoint: Pathological complete response rate (pCR). Planned start Jun 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecancamrelizumab
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on ChiCTR2600126897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126897.